Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-851-8 | CAS number: 111-26-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
oral:
In a read across study the NOAEL for octylammonium chloride after repeated oral application was determined to be 100 mg/kg bw in rats.
inhalation:
The LOAEC for repeated inhalation of the read across substance butylamine was determined to be 51 mg/m3 in rats.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- combined repeated dose and reproduction / developmental screening
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2005-10-12 through 2007-07-30
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study with acceptable restrictions. Please refer to section 13 (read across statement).
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl:CD (SD) IGS BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc., Raleigh, NC
- Age at study initiation: 81 days
- Weight at study initiation: 355.2 - 450.2 grams (males) and 196.3 - 309.0 grams (females)
- Fasting period before study: 15 hours (only animals from which samples were taken for clinical pathology evaluation: hematology, clinical chemistry, and urinalysis)
- Housing: individually during non-mating periods
- Diet: PMI Nutrition International, Certified Rodent LabDiet 5002 ad libitum, except when fasted
- Water: ad libitum
- Acclimation period: 28 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-26
- Humidity (%): 30-70
- Photoperiod (hrs dark / hrs light): 12/12
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
- mixing of test substance with NanoPure water (procedure documented in the study records)
- pH was adjusted to values between 4.0 an 6.0 prior to dosing
- Storage: refrigerated up to 7 days of the low, intermediate,and high dose solution
- stability: demonstrated (Appendix C)
- Dose volume: 4 mL/kg bw
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dosing samples were diluted to a concentration of 0.100 mg/mL; the pH was adjusted with 8 N NaOH, the samples were then extracted with toluene containing decylamine as internal standard. Sample analysis was performed using Gas Chromatography (cf. Appendix C for details).
- Duration of treatment / exposure:
- Males: 47-48 days/Females: 42-46 days
- Frequency of treatment:
- daily
- Remarks:
- Doses / Concentrations:
0 (Vehicle), 37.5, 75, and 150/100 mg/kg/day
Basis:
actual ingested - No. of animals per sex per dose:
- 12
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on the results of two range-finding studies
- Positive control:
- not required
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least daily
DETAILED CLINICAL OBSERVATIONS: Yes
BODY WEIGHT: Yes
- Time schedule for examinations: once during pretets (baseline) and weekly thereafter. Observations included (but were not limited to) evaluation of fur, skin, eyes, mucous membranes, occurrence of secretions and excretions, autonomic nervous system activity (lacrimation, piloerection, and unusual respiratory pattern), changes in gait, posture, response to handling, presence of clonic, tonic, stereotypical, or bizarre behavior.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): not applicable
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: test days 13-14; coagulation at study termination, test days 42-47
- Anaesthetic used for blood collection: Yes (carbon dioxide)
- Animals fasted: Yes
- How many animals: all F0 animals
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: test days 13-14
- Animals fasted: Yes
- How many animals: all F0 animals
URINALYSIS: Yes
- Time schedule for collection of urine: test days 13-14
- Metabolism cages used for collection of urine: Yes
- Animals fasted: Yes
NEUROBEHAVIOURAL EXAMINATION: Yes
- Prior to tretment: test days 7-8 (males and females)
- Prior to the end of the premating period: test days 12-13 (males and females)
- No. of replicates: 4 for each evaluation
- Dose groups that were examined: all groups, all animals
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes
- Reproductive organs: all (12/sex/dose) control and high dose animals
- Other tissues: from randomly selected animals (5/sex/dose)
- Trachea: from all adult rats
- Pups: no microscopical examinations - Statistics:
- Primarily, Levene's test for homogeneity, one-way analysis of variance, Dunnett's test, Kruskal-Wallis test, Dunn's test and Cochran-Armitage test for trend
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- effects observed, treatment-related
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- effects observed, treatment-related
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- EFFECTS BY DOSE LEVEL:
Low dose group: 37.5 mg/kg bw/day:
F0 parental animals
CLINICAL EXAMINATIONS/CLINICAL PATHOLOGY/URINALYSIS/PATHOLOGY
-statistically significant reductions in body weights (-6%) and body weight gain (-17%) in males from the first week to the end of the study
- slight (not statistically significant) reductions in body weights (-2%/-8%) and body weight gain (-48%/-14%) in females as compared with controls, during premating and gestation, respectively.
-statistically significant reductions in food consumption (-6%) in males during premating
-slight (not statistically significant) reductions in food consumption in females during premating (-8%) and gestation (-12%)
-statistically significant decrease in hemoglobin concentration on day 14 in females, minimal (-4%), not dose-related
-minimal tracheal lesions in males, dosing-related, likely the result of topical exposure to the test substance
Intermediate dose group, 75 mg/kg bw/day:
F0 parental animals
CLINICAL EXAMINATIONS/CLINICAL PATHOLOGY/URINALYSIS/PATHOLOGY
-salivation in 7/12 males and in 1/12 females during premating
-statistically significant reductions in body weights (-6%) and body weight gain (-20%), as compared with controls, in males from the first week to the end of the study
-slight (not statistically significant) reductions in body weights (-3%/-6%) and body weight gain (-27%/-10%) as compared with controls, in females during premating and gestation, respectively
-statistically significant reductions in food consumption (-8%) in males during premating
-slight (not statistically significant) reductions in food consumption in females during premating (-9%) and gestation (-12%)
-minimal tracheal lesions in males and females, dosing-related, likely the result of topical exposure to the test substance
High dose group, 150/100 mg/kg bw/day:
F0 parental animals:
MORTALITY:
Two female rats and one male rat in the150 mg/kg/day group were found dead on test days 8 to 12. Autopsy suggested a dosing accident aggravated by the irritation from the test substance.
CLINICAL EXAMINATIONS/CLINICAL PATHOLOGY/URINALYSIS/PATHOLOGY
-salivation in 12/12 male animals, in 12/12 females during premating, and in 2/12 females during gestation
-irregular respiration, lung noise, and fur-staining (face and nose). Diarrhea, gasping, hunched-over posture, weakness, and abnormal gait/mobility in one male
-statistically significant reductions in body weights (-12%) and body weight gain (-43%) as compared with controls, in males from the first week to the end of the study
-slight (not statistically significant) reductions in body weights (-2%/-7%) and body weight gain(-41%/-11%) as compared with controls, in females during premating and gestation, respectively
-statistically significant reductions in food consumption (-13%) in males during premating
-slight (not statistically significant) reductions in food consumption in females during premating (-8%) and gestation (-11%)
-minimal to mild tracheal lesions in males and females, dosing-related, likely the result of topical exposure to the test substance
-statistically significant decrease in mean cell hemoglobin concentration (-1%) on day 14 in females, without associated changes in other white blood cell parameters, not treatment-related
-statistically significant increase in eosinophils (200%) on day 13 in males, without associated changes in other white blood cell parameters or
correlative histologic changes, possibly treatment-related, but not considered adverse
-statistically significant decrease in absolute heart weight (-13%) as compared with controls, in males accompanied by slight (not significant)
decreases in most other absolute and relative organ weights in males and females, all without microscopic changes and probably related to overall decrease in body weights
-statistically significant increase in relative adrenal gland (36%) and testes (14%) weights in males, without microscopic changes - Dose descriptor:
- NOAEL
- Effect level:
- ca. 100 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: clinical signs; mortality; body weight; food consumption; food efficiency; haematology; clinical chemistry; urinalysis; gross pathology; organ weights; histopathology
- Critical effects observed:
- not specified
Reference
Body weight
Compared to controls, body weight was slightly reduced in treated groups, reaching a level of statistical significance in males. The biological relevance is, however low, because the changes are small and are paralleled by reductions in food consumption which can explain the body weight reductions, rather than test substance-related toxicity.
Table 1: Bodyweights
|
Males |
Females |
||||
Dose (mg/kg bw/day) |
37.5 |
75 |
150/100 |
37.5 |
75 |
150/100 |
Reduction body weight (%) |
-6* |
-6* |
-12* |
-2 (premating) -8 (gestation) |
-2 (premating) -6 (gestation) |
-2 (premating) -7 (gestation) |
Reduction food consumption (%) |
-6* |
-8* |
-13* |
-8 (premating) -12 (gestation) |
-9 (premating) -12 (gestation) |
-8 (premating) -11 (gestation) |
Clinical signs
The incidence of clinical signs was as follows:
Table 2: clinical signs
|
Male |
Female |
||||||
Dose (mg/kg bw/day) |
0 |
37.5 |
75 |
150/100 |
0 |
37.5 |
75 |
150/100 |
Number of rats at sacrifice |
12 |
12 |
12 |
11 |
12 |
12 |
12 |
10 |
Weak, hunched position |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
1 |
Lung noise |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
1 |
Salivation |
0 |
0 |
7 |
12 |
0 |
0 |
1 |
12 |
Microscopic Findings
Dosing-related microscopic findings were observed in the trachea (mucosal metaplasia, hyperplasia, and inflammation) of males and females at all dose levels. However, these tracheal lesions were interpreted to be the result of inadvertent direct exposure of the trachea to the test substance during dosing and not the effect of gavage exposure. Therefore, these microscopic findings were not test substance-related in the context of a gavage study.
Table 3: Incidences of Dosing-Related Microscopic Findings in Male and Female Rats
|
Male |
Female |
||||||
Dose (mg/kg bw/day) |
0 |
37.5 |
75 |
150/100 |
0 |
37.5 |
75 |
150/100 |
Number of rats at sacrifice |
12 |
12 |
12 |
11 |
12 |
12 |
12 |
10 |
Trachea |
|
|
|
|
|
|
|
|
Metaplasia, mucosal |
1 |
4 |
11 |
7 |
1 |
1 |
5 |
6 |
Hyperplasia, mucosal |
0 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
Inflammation, mucosal |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
The authors interpreted the underlined to be dosing-related increases in microscopic findings.
Trachea
Squamous metaplasia of the proximal to mid-cervical trachea was observed in more than half of the male (18/23) and female (11/22) rats given >/= 75 mg/kg/day and in one-third (4/12) of the male rats given 37.5 mg/kg/day of the test substance. All cases were graded as minimal (grade 1 of 4), except for two males (one each at 75 and 150/100 mg/kg/day) that were graded as mild
The metaplasia consisted of the partial replacement of the normal ciliated pseudostratified columnar epithelium (i.e., respiratory epithelium) on the ventral and lateral aspects of the tracheal mucosa with deciliated round and/or flattened epithelial cells resembling mucous membrane. In two males (one each at 37.5 and 75 mg/kg/day), the metaplasia was associated with minimal hyperplasia. In two females (one each at 75 and 150/100 mg/kg/day), the metaplasia was associated with minimal inflammation.
The minimal to mild squamous metaplasia, and associated hyperplasia and inflammation, was probably the result of transient topical exposure of the tracheal mucosa to the test substance following gavage administration. These minimal to mild lesions in surviving rats contrast with the moderate (grade 3 of 4) to severe (grade 4 of 4) tracheal ulceration and inflammation observed in the two decedent females that died following accidental administration of the test substance to the trachea.
The minimal to mild metaplasia observed in the surviving rats was interpreted to be a nonadverse adaptive response, most likely reversible, which was due to transient esophageal reflux or imperfect dosing. The four incidences of minimal tracheal inflammation or hyperplasia were also considered to be artifacts of the dosing procedure rather than test-substance related effects.
Other
All other microscopic observations in this study were consistent with normal background lesions in rats of this age and strain.
One neoplasm occurred in this study. A malignant renal mesenchymal tumor was observed in a kidney from a high-dose female rat (Animal Number 805). Although this is an uncommon neoplasm, the individual occurrence was considered to be incidental and not test substance related.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 100 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- OECD Guideline Studies, sufficient for assessment
Repeated dose toxicity: inhalation - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP and Guideline study Please refer to section 13 (read across statement).
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 412 (Subacute Inhalation Toxicity: 28-Day Study)
- Deviations:
- yes
- Remarks:
- according to OECD Guideline 414 (Prenatal Developmental Toxicity Study) [see 7.8.2]
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: K. Thomae GmbH/Boehringer Ingelheim, Biberach/Germany
- Age at study initiation: approx. 70 d
- Weight at study initiation: 198 - 246 g
- Housing: single
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 5 d before mating
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 24
- Humidity (%): 30 - 70
- Photoperiod (hrs dark / hrs light): 12 / 12 - Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus:glass-steel inhalation exposure chamber, 1.4 m3, space for 6x6 cages
- Method of holding animals in test chamber: 1 animal/cage
- Source and rate of air: charcoal-filtered air
- System of generating particulates/aerosols: In a thermostated vaporiser (25 - 35 °C), the vapor-air mixture was generated by spraying the TS
with compressed air into a counter current of conditioned air, followed by further mixing with air to achieve required
exposure concentrations.
- Temperature, humidity, pressure in air chamber: 21.2 - 22.5 °C; 50.5 - 62.0 %
- Air change rate: Air changes: 20/hour
TEST ATMOSPHERE
- Brief description of analytical method used: GC/FID after absorption in DMF
- Samples taken from breathing zone: yes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- - Method: GC with FID detection
- Sampling time: 2 times during each exposure (for controls 2 times during the study) - Duration of treatment / exposure:
- 14 d (6 - 19 day of gestation)
- Frequency of treatment:
- 6 h/d
- Remarks:
- Doses / Concentrations:
51.4 +-2.2; 151.8 +-9.2; and 460 +-17.5 mg/m3 (= 17, 50.1, and 151.8 mL/m3)
Basis:
analytical conc. - No. of animals per sex per dose:
- 20 - 24 pregnant female rats
- Control animals:
- yes, concurrent no treatment
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: 3x during exposure, other days 1x
BODY WEIGHT: Yes
- Time schedule for examinations: on day 1, 3, 6, 8, 10, 13, 15, 17, 19 and 20
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: ovary, uterus, placenta
- macroscopy of dams
- histopathological examination of 4 sections of the nasal cavity - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- - Mortality: none
- Body weight: no treatment related effects
- Clinical signs: no treatment related effects
- Gross pathology incidence and severity: no treatment related effects [incidental congestion, oedema and/or marginal emphysema of the lungs (due to method of sacrifice)
- Histopathology incidence and severity: anterior nasal section showing squamous metaplasia, inflammatory cells and hyperplasia of transitional cells at all concentrations (dose dependent effect). At 450 mg/m3, necrosis of the nasal mucosa (5 animals) and the underlying nasal bone (1 animal). - Dose descriptor:
- NOAEC
- Effect level:
- > 17 ppm
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Histopathology: nasal irritation
- Dose descriptor:
- NOAEC
- Effect level:
- > 51 mg/m³ air (analytical)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Histopathology: nasal irritation
- Dose descriptor:
- LOAEC
- Effect level:
- 51 mg/m³ air (analytical)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Histopathology: nasal irritation
- Critical effects observed:
- not specified
Reference
Table 1: Nasal irritation in dams following inhalation exposure to n-butylamine during gestation (14 d)
Percentage of dams showing lesions exposed to the following concentrations in ppm [mg/m3], nominal |
||||
Histopathological findings |
0 |
17 [50] |
50 [150] |
150 [450] |
Squamous cell metaplasia |
No data |
10 |
50 |
100 |
Purulent to mixed inflammatory cell infiltration |
No data |
30 |
90 |
100 |
Focal necrosis of nasal mucosa |
No data |
0 |
0 |
50 |
Necrosis of nasal bone |
No data |
0 |
0 |
10 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LOAEC
- 51 mg/m³
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- GLP guideline study with acceptable restrictions and summary of Guideline study
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Oral
A read across study is available in which Octylamine-HCl was examined for its potential for repeated dose toxicity, developmental and neurotoxicity in a combined OECD TG 422 study under GLP conditions. The dose levels used (0, 37.5, 75, an 100/150 mg/kg bw/day; oral gavage; 12 rats/sex/dose) were selected based on the results of two range finding studies, one in the range 100-1000 mg/kg bw/day, and one in the range 3-100 mg/kg bw/day. The high dose group was initially dosed at 150 mg/kg bw/day, but this was lowered 100 mg/kg bw/day by test day 14 because two mortalities were seen in this group. Therefore, this dose level is called “100/150 mg/kg bw/day”. It should however be mentioned that subsequent examinations revealed that these mortalities resulted from maldosing and were not related to the test substance. Thus, there were no substance-related mortalities in this study, and with few exceptions there were no changes in clinical signs of toxicity, clinic-chemical parameters, hematology, urinalysis, gross observations, organ weights, and histopathology that were attributable to the test substance and of statistical or biological relevance. Effects on male and female body weight, clinical signs including salivation, and changes in the trachea were observed as follows: Minimal to mild squamous metaplasia, and associated hyperplasia and inflammation, was seen in all treated groups. The minimal to mild metaplasia observed in the surviving rats was interpreted to be a nonadverse adaptive response, most likely reversible, which was due to transient esophageal reflux or imperfect dosing. The four incidences of minimal tracheal inflammation or hyperplasia were also considered to be artifacts of the dosing procedure rather than test substance-related effects. Lung noise was observed only in high dose rats. Weak animals showed also lung noise or noisy respiration. Maldosing or reflux cannot be excluded to be responsible for lung noise, as tracheal metaplasia was seen in 2 of the 4 animals which showed lung noise. Salivation in mid dose males was seen on individual days scattered over the entire study period, and lasted only one day (e.g. day 2-2; day 36-36; etc.). At the high dose, salivation was seen in all animals and persisted for several days. This could result from bad taste, but the biological relevance is, however, not clear. Compared to controls, body weight was slightly reduced in treated groups, reaching a level of statistical significance in males. The biological relevance is, however, low because the changes are small and are paralleled by reductions in food consumption which can explain the body weight reductions, rather than test substance-related toxicity. Based on the above, and taking results of the range-finding studies into consideration, it is concluded that the test substance (octylamine hydrochloride; pH adjusted to 4.0-6.0; dose volume 4 mL/kg bw) was irritating. It caused respiratory problems and tracheal irritation after maldosing and/or reflux. The food intake was slightly reduced and led to slight reductions of body weight and body weight gain. The observed clinical signs and slightly reduced body weights are therefore considered to be secondary, rather than to reflect systemic toxicity of the test substance. Therefore, the NOAEL for systemic toxicity was considered to be 100 mg/kg bw/day under the conditions of this study.
Inhalation
In a 14 days repeated dose inhalation study on rats, 20-24 pregnant female animals were exposed to concentrations of 51.4 +/-2.2; 151.8 +/-9.2; and 460 +/-17.5 mg/m3 (analytically verified) for 6 hours/day to the read across substance butylamine. No effects on mortality and body weight and no clinical signs were observed. Nasal irritation was observed in all dose groups. Based on these results, the LOAEC was determined to be 51 mg/m3 (17 ppm) air and the NOAC was determined to be >17 ppm.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Only one study availabale
Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
Only one study available
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No 1272/2008
The available experimental test data are reliable and suitable for classification purposes under Regulation (EC) No 1272/2008. As a result the substance is not considered to be classified for repeated dose toxicity under Regulation (EC) No 1272/2008, as amended for the sixth time in Directive EC 605/2014.
Dangerous Substance Directive (67/548/EEC)
The available study is considered reliable and suitable for classification purposes under 67/548/EEC. As a result the substance is not considered to be classified for repeated dose toxicity under Directive 67/548/EEC, as amended for the 31st time in Directive 2009/2/EG.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.